N/A N=135 Investigation of Mohs Surgical Margins Using Two Photon Microscopy
Basal Cell Carcinoma
Primary: Agreement Between Frozen Sections and Two Photon Fluorescence Microscopy on Mohs Margins — 72.7; 96.8 Percentage
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=82 3D Printed Models in Mohs Micrographic Surgery
Mohs Micrographic Surgery
Primary: Percent of Correct and Incorrect Mohs Quiz Responses — 93.25; 85.83; 6.75; 14.17 Percent of quiz responses — p=0.007
N/A N=14 Absorbable Suture Versus Tissue Glue to Repair Defects Following Mohs Surgery
Basal Cell Carcinoma · Squamous Cell Carcinoma
Primary: Visual Analog Scale (VAS) — 7.47; 7.97 units on a scale
Phase 2 N=1 Vismodegib for Treatment of Basal Cell Carcinoma
Basal Cell Carcinoma
Primary: Mohs Micrographic Surgery (MMS) — 1 mm
N/A N=30 Post Excision/Mohs Scar Laser Resurfacing
Skin Cancer
Primary: MMSS for Scar Halves Treated — 8.4; 8.7 score on a scale
Phase 2 N=8 Healing Effects of HP802-247 Versus Antibiotic Ointment in Mohs Micrographic Surgery Patients
Non-melanoma Skin Cancer
Primary: The Primary Efficacy Measure Was the Investigator's Global Assessment of Healing (IGAH). — 2.75; 2.25; 3.00; 3.00 units on a scale — p=0.263
N/A N=369 Comparison of eBX and Mohs Surgery for Treatment of Early-stage Non-melanoma Skin Cancer a Matched Pair Cohort Study.
Nonmelanoma Skin Cancer
Primary: Absence of Local Recurrence at Treatment Site(s) Greater or Equal to 3 Years Follow-up — 188; 181; 187; 181 participants
N/A N=19 Serum Concentration of Lidocaine After Local Injection During Mohs Micrographic Surgery
Basal Cell Carcinoma · Squamous Cell Carcinoma
Primary: The Number of Subjects With Detectable Serum Lidocaine Concentrations (<0.1 ug/mL) at Each Blood Draw. — 0; 1; 0; 2 Participants
Early Phase 1 N=124 Topical Tranexamic Acid Use on Granulating Wounds Following Mohs Micrographic Surgery
Postoperative Wound Haemorrhage
Primary: Frequency of Postoperative Hemorrhagic Complications — 0; 6 Participants — p=.028
N/A N=30 CellFX Treat & Resect Low-Risk BCC Feasibility Study
BCC - Basal Cell Carcinoma · BCC · Excision Margin
Primary: Number of Lesions With BCC Histological Clearance — 34 BCC Lesions
N/A N=33 Long-pulsed 1064 nm Nd:YAG Laser Treatment of Basal Cell Carcinoma
Basal Cell Carcinoma
Primary: This is a Study to Measure the Efficacy of the Nd:YAG Laser to Cause Complete Regression of Basal Cell Carcinoma. — 28 tumors
Phase 2 N=20 Topical Laser-assisted Combination Chemotherapy for Basal Cell Carcinoma- a Clinical Study
Carcinoma, Basal Cell
Primary: Change in Occurence of Local Skin Reaction (LSR) Side Effects TOTAL COMPOSITE SCORE — 7; 9; 4; 2 score on a scale
N/A N=776 A Retrospective Evaluation of Superficial Radiation Therapy (SRT) and Non-Melanoma Skin Cancer (NMSC)
Non-melanoma Skin Cancer
Primary: Cure Rate — 751 lesions
Phase 4 N=35 VISmodegib for ORbital and Periocular Basal Cell Carcinoma
Carcinoma, Basal Cell
Primary: The Number of Patients With a Score of 21 or Greater by the Visual Assessment Weighted Score (VAWS). — 34 Participants
Phase 4 N=40 Comparison of Excision Versus Punch Incision in the Treatment of Epidermal Cysts
Epidermal Cyst
Primary: Number of Participants With Cyst Recurrence — 3; 2 participants
N/A N=37 Enhanced Secondary Intention Healing vs. Standard Secondary Intention Healing in Mohs Surgical Defects on the Head and Distal Lower Extremities
Wound Heal
Primary: Time to Complete Wound Re-epithelialization on the Head — 41.6; 43 days
Phase 4 N=233 Lidocaine Jelly for Pain Control During Mohs Surgery
Pain · Satisfaction, Consumer
Primary: Mean Change in Patient Perception of Pain Score — 0.5; 0.3 score on a scale
Phase 2 N=12 Study of EB-001 in Facial Scar Reduction
Mohs Surgery
Primary: Assessment of Visual Analog Scale (VAS) Change (Values From 0 (Worst) to 10 (Best)) — 0; 50 Percentage reporting improvement
N/A N=12 Randomized Pilot Study of Treatment for BCC Using the Multiplex 595/1064 nm Laser
Nodular Basal Cell Carcinoma · Superficial Basal Cell Carcinoma
Primary: Percentage of Lesions Cleared Histologically — 3; 5 Lesion
Early Phase 1 N=15 Vismodegib in Treating Patients With Basal Cell Carcinoma (BCC)
Basal Cell Carcinoma of the Skin · Recurrent Skin Cancer
Primary: Percent Change in Surgical Defect Area After the Treatment Period Using Calipers and Photographs Was Calculated — -26.8 percentage size change from baseline
N/A N=48 Evaluating the Safety and Efficacy of Fractionated Carbon Dioxide Therapy in Postoperative Lower Extremity Wound Healing
Leg Ulcer
Primary: Number of Participants With Completely Healed Lower Extremity Wounds — 20; 18 Participants
N/A N=90 Combination Therapy With Imiquimod Cream 5% and Tazarotene Cream 0.1% for the Treatment of Lentigo Maligna
Cancer · Lentigo Maligna
Primary: The Absence of Lentigo Maligna (LM) at the Time of Staged Excisions in Participants — 27; 29 participants
Phase 3 N=120 Metvix Photodynamic Therapy (PDT) Versus Cryotherapy in Participants With Primary Superficial Basal Cell Carcinoma
Superficial Basal Cell Carcinoma
Primary: Percentage of Participants With Histologically Confirmed Patient Complete Response (CR) 3 Months After Last Metvix PDT or Cryotherapy Cycle — 92; 90 percentage of…
Phase 3 N=60 Cryosurgery and Cream Combination for Actinic Keratosis
Actinic Keratosis
Primary: Number Participants With 100% Clearance — 12; 13 Participants
Phase 3 N=102 Metvix PDT in Participant With "High Risk" Basal Cell Carcinoma
Basal Cell Carcinoma
Primary: Percentage of Participants With Histologically Confirmed Patient Complete Response (CR) 3 Months After Last Metvix PDT Cycle — 80 percentage of participants
N/A N=150 CellFX Comparison to Cryosurgery in Cutaneous Non-Genital Common Warts
Warts · Warts Hand · Verruca
Primary: Percentage of Warts Resolved — 80.7; 73.1 percentage of warts resolved
Phase 2 N=28 Study Evaluating the Efficacy of Oral Vismodegib in Various Histologic Subtypes
Basal Cell Carcinoma
Primary: Efficacy of Vismodegib — 2; 5; 1; 1 tumors
N/A N=40 Safety of Microporous Annealed Particle (MAP) Wound Matrix in Patients With Clean Surgical Wounds.
Wound Heal
Primary: Incidence of Serious Adverse Device Effects in the Treatment Group Compared to the Control Group. — 0; 0 Participants
N/A N=15 Cetuximab Before Surgery in Treating Patients With Aggressive Locally Advanced Skin Cancer
Recurrent Skin Cancer · Squamous Cell Carcinoma of the Skin
Primary: Response Rate of Cetuximab by RECIST Criteria — 15 Participants
Phase 3 N=162 Photodynamic Therapy (PDT) With Metvix® 160 Milligrams/Gram Cream in Organ Transplant Participants With Non-melanoma Skin Cancer
Actinic Keratosis · Warts · Basal Cell Carcinoma
Primary: Number of Accumulated New Skin Lesions at Month 3 — 65; 103 new skin lesions — p=0.0120